Join our community of smart investors

GSK and Google join forces in bioelectronics project

The pharma behemoth and global technology leader have entered into a joint venture to try to discover disease treatments by combining their biological and electronic expertise
August 5, 2016

Pharmaceutical giant GlaxoSmithKline (GSK) has become something of a shining light in the gloom of post-referendum Britain. Amid the big FTSE sell-off immediately after the vote, GSK saw its share price soar as investors looked to park their cash in a perceived safe-haven, high-income stock. Last week, chief executive Andrew Witty announced that the group would spend £275m on revamping its UK science sites; a relief for those concerned that Brexit could be a drain on the nation's scientific capabilities. Now, the group is teaming up with Verily - a lifescience outlet of Google's parent company, Alphabet (US:GOOGL) - to create a groundbreaking new venture; Galvani Bioelectronics.

IC TIP: Hold at 1670p

Bioelectronics - otherwise known as electroceuticals - aims to tackle a wide range of diseases using tiny computerised implants to stimulate the nervous system. Historically, the technique has been used to repair brain and spinal cord circuits and has successfully given patients the ability to control bionic limbs using their mind. But GSK and Verily together want to go one step further and "miniaturise implants down to the size of a grain of rice" in order to stimulate the peripheral nervous system to treat chronic diseases such as diabetes, arthritis and asthma.

To continue reading...
REGISTER FOR FREE TODAY
  • Read 3 articles for free each month
  • Educational articles and topical investment guides
  • In-depth podcast episodes by our writers and industry professionals
  • Interactive live webinars on investment themes that matter
Have an account? Sign in